GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Equity-to-Asset

Insulet (Insulet) Equity-to-Asset

: 0.28 (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Insulet's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $733 Mil. Insulet's Total Assets for the quarter that ended in Dec. 2023 was $2,588 Mil. Therefore, Insulet's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.28.

The historical rank and industry rank for Insulet's Equity-to-Asset or its related term are showing as below:

PODD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07   Med: 0.22   Max: 0.32
Current: 0.28

During the past 13 years, the highest Equity to Asset Ratio of Insulet was 0.32. The lowest was 0.07. And the median was 0.22.

PODD's Equity-to-Asset is ranked worse than
86.22% of 871 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs PODD: 0.28

Insulet Equity-to-Asset Historical Data

The historical data trend for Insulet's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 0.07 [6] => 0.32 [7] => 0.27 [8] => 0.21 [9] => 0.28 )
Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.32 0.27 0.21 0.28

Insulet Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.22 0.23 0.25 0.28

Competitive Comparison

For the Medical Devices subindustry, Insulet's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet Equity-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Insulet's Equity-to-Asset falls into.



Insulet Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Insulet's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=732.7/2588.2
=0.28

Insulet's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=732.7/2588.2
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insulet  (NAS:PODD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Insulet Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Insulet's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (Insulet) Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Executives
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche officer: SVP, Global Manufacturing C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen officer: SVP and CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears officer: SVP, Quality and Regulatory C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine director C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford director C/O HOLOGIC, INC., BEDFORD MA 01730

Insulet (Insulet) Headlines

From GuruFocus

Q2 2022 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Insulet Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024